CSIMarket
 
Alx Oncology Holdings Inc  (ALXO)
Other Ticker:  
 
 
Price: $11.3000 $0.15 1.345%
Day's High: $11.68 Week Perf: -16.05 %
Day's Low: $ 10.96 30 Day Perf: -28.66 %
Volume (M): 547 52 Wk High: $ 17.42
Volume (M$): $ 6,177 52 Wk Avg: $8.58
Open: $11.14 52 Wk Low: $3.94



 Market Capitalization (Millions $) 465
 Shares Outstanding (Millions) 41
 Employees 17
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -146
 Cash Flow (TTM) (Millions $) -29
 Capital Exp. (TTM) (Millions $) 3

Alx Oncology Holdings Inc
Alx Oncology Holdings Inc is a clinical-stage biotechnology company that focuses on developing treatments for cancer. The company's approach centres on harnessing the power of the immune system to fight tumours. Alx Oncology is based in Burlingame, California, and is publicly traded on Nasdaq under the symbol "ALXO."

The company's lead product candidate, ALX148, is an immune checkpoint inhibitor. It works by blocking the CD47 protein, which is typically upregulated on cancer cells, thereby preventing them from evading immune system recognition and destruction. Preclinical data suggest that targeting CD47 can enhance the efficacy of other cancer therapies, such as chemotherapy, and improve patient outcomes.

Alx Oncology is pursuing a broad clinical development program for ALX148 across a range of solid and hematologic tumours. The company's ongoing clinical trials include combination studies with standard-of-care treatments, such as doxorubicin and rituximab, as well as investigational agents, such as anti-PD-1 and anti-PD-L1 antibodies. ALX148 has shown promising results in early-stage trials, prompting the company to advance several clinical programs into later stages of development.

In addition to ALX148, Alx Oncology has a pipeline of other CD47-targeting candidates under preclinical evaluation. The company's early research suggests that these compounds may have unique pharmacologic properties and could further improve cancer therapy outcomes.

Alx Oncology's business model centres on partnering with established biopharmaceutical companies to develop and commercialize its drug candidates. The company has license agreements with several major pharma companies, including Genentech, a member of the Roche Group, and Alexion Pharmaceuticals.

Overall, Alx Oncology Holdings Inc is a rapidly growing biotech company offering a promising approach to cancer therapy through its innovative CD47-targeting technology. The company has a strong cash position, a seasoned management team, and a broad network of collaborators, positioning it to become an industry leader in cancer immunotherapy.


   Company Address: 323 Allerton Avenue South San Francisco 94080 CA
   Company Phone Number: 466-7125   Stock Exchange / Ticker: NASDAQ ALXO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

ALX Oncology's Evorpacept Advances with Promising Clinical Data at AACR Annual Meeting

Published Tue, Mar 5 2024 9:30 PM UTC

ALX Oncology Holdings Inc's Evorpacept, a novel therapeutic candidate for the treatment of cancer, has achieved significant progress with the acceptance of two clinical abstracts for presentation at the upcoming AACR Annual Meeting. One of the abstracts highlights an investigator-initiated trial involving patients with relapsed or refractory B-cell non-Hodgkin lymphoma, whic...

Alx Oncology Holdings Inc

ALX Oncology Holdings Inc. Leads the Pack with Exciting Third Quarter Results in 2023

In the face of an ongoing reporting cycle, it is evident that the Major Pharmaceutical Preparations sector has faced significant challenges. ALX Oncology Holdings Inc, a prominent player in this sector, recently announced an alarming operating loss of $-53.275 million for the most recent fiscal period. This news raises concerns among investors who eagerly await the company's strategic plan to address these financial setbacks.
It is important to note that shareholders cannot rely solely on the recent productivity improvement at ALX Oncology Holdings Inc. Despite efforts by the CEO to implement various financial plans, the expanding deficit has worsened from $-35.320 million to $-50.990 million compared to the previous quarter. Such a substantial increase in losses is a clear indication of the company's struggles in maintaining a steady product line.

Shares

ALX Oncology's Successful Pricing of Public Offering Sparks Investor Enthusiasm for Cutting-Edge Immuno-Oncology Initiatives

Published Thu, Oct 5 2023 12:01 PM UTC



ALX Oncology Holdings Inc., a leading immuno-oncology company aiming to combat cancer by blocking the CD47 immune checkpoint pathway, recently revealed the pricing details of its highly anticipated underwritten public offering. With a focus on developing groundbreaking therapeutics, ALX Oncology aims to leverage the proceeds of this offering to accelerate its robus...

Alx Oncology Holdings Inc

Alx Oncology Holdings Inc. Reports Robust Q2 2023 Earnings, Cementing its Dominance in the Major Pharmaceutical Preparations Industry

The stock market has always been a fascinating place, full of twists and turns that keep investors on their toes. One company that has recently caught the attention of shareholders is Alx Oncology Holdings Inc. Although the shareholders have not assumed any significant changes in the top-line revenue during the April to June 2023 reporting cycle, there are some recent developments that have ignited a spark of curiosity among market observers.
One aspect that cannot be ignored is the operating shortfall of Alx Oncology Holdings Inc. The Major Pharmaceutical Preparations company has experienced a slight decline in its operating performance, with a shortfall of $-36.777 million during the second quarter of 2023. This represents a deterioration from the $-33.789 million recorded in the same period of 2022. While these figures may seem concerning on the surface, it's important to remember that corporations often face challenging periods as they navigate the complexity of developing a prosperous business strategy.

Alx Oncology Holdings Inc

1. Major Pharmaceutical Preparations Company Reports Operating Deficit of $-32.203 Million in Q1 2023

The pharmaceutical industry has been a cornerstone of the global economy for decades. However, recent reports from Alx Oncology Holdings Inc are cause for concern. The rising corporation announced an operating deficit of $-32.203 million in the first quarter of 2023, a significant increase from the same period in the previous year.
Alx Oncology Holdings Inc has not yet disclosed its revenue for the first quarter of 2023, but by comparing corporate performance through the first quarter of 2022, it is clear that the company is in dire straits. In fact, the company announced an operating deficit of $-24.747 million in the same period last year. This staggering increase in losses over the year is alarming, to say the least.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com